Berkshire’s Cash Bulk… And New Data In The Weight Loss Drug Race 11/4/24

Jim Bianco, President and Macro Strategist at Bianco Research, shares insights on Warren Buffett’s recent cuts to big-name stocks, pondering the implications for the market. They discuss Viking Therapeutics’ promising data on its weight loss drug, and what that means for competition in the sector. The conversation delves into how investor behavior is shifting amid rising economic uncertainties and dissecting the impact of upcoming elections on fiscal policy and stock performance, particularly in the semiconductor industry.